Clinical Cancer Research Molecular Diagnostics in Cancer Therapeutic Development: Fulfilling the Promise of Personalized Medicine Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dhar, S.
Right arrow Articles by Band, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dhar, S.
Right arrow Articles by Band, V.
Clinical Cancer Research Vol. 7, 3393-3398, November 2001
© 2001 American Association for Cancer Research


Regular Articles

Analysis of Normal Epithelial Cell Specific-1 (NES1)/Kallikrein 10 mRNA Expression by in Situ Hybridization, a Novel Marker for Breast Cancer1

Sanjay Dhar, Rohit Bhargava, Michael Yunes, Biao Li, Jaya Goyal, Stephen P. Naber, David E. Wazer and Vimla Band2

Division of Radiation and Cancer Biology, Department of Radiation Oncology, New England Medical Center, Boston, Massachusetts 02111 [S. D., M. Y., B. L., J. G., D. E. W., V. B.]; Department of Biochemistry, Tufts University School of Medicine, Boston, Massachusetts 02111 [V. B.]; and Baystate Medical Center, Springfield, Massachusetts [R. B., S. P. N.]

Purpose: Normal epithelial cell specific-1 (NES1)/kallikrein 10 gene is expressed in normal mammary and prostate epithelial cells, but the expression of NES1 mRNA and protein is markedly reduced in established breast and prostate cancer cell lines although the NES1 gene is intact. Here, we wished to assess whether NES1 expression is down-regulated in primary breast cancers.

Experimental Design: We developed and used an in situ hybridization technique with an antisense NES1 probe to detect NES1 mRNA in sections of normal breast specimens, typical and atypical ductal hyperplasia, ductal carcinoma in situ, and infiltrating ductal carcinoma.

Results: All of the 30 normal breast specimens showed high NES1 expression. Notably, 18 (75%) of 24 typical and atypical breast hyperplasia specimens showed high NES1 expression, with weak-to-moderate expression in 6 (25%). Significantly, 13 (46%) of 28 ductal carcinoma in situ specimens lacked NES1 expression, and the remaining 15 (54%) showed weak-to-moderate expression. Finally, 29 of 30 (97%) infiltrating ductal carcinoma grades I-III samples lacked NES1 mRNA, with weak expression in the remaining one sample.

Conclusions: Our results demonstrate that NES1 mRNA is expressed in normal breast tissue and benign lesions, with loss of NES1 expression during tumor progression. We suggest that NES1 expression may serve as a molecular tool in the study of breast cancer progression. Studies with larger series of specimens should help assess whether NES1 expression can be a diagnostic and/or prognostic marker in breast and other cancers.




This article has been cited by other articles:


Home page
J. Histochem. Cytochem.Home page
M. H. Slagter, L. J.G. Gooren, A. Scorilas, C. D. Petraki, and E. P. Diamandis
Effects of Long-term Androgen Administration on Breast Tissue of Female-to-Male Transsexuals
J. Histochem. Cytochem., August 1, 2006; 54(8): 905 - 910.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. J. Fackler, M. McVeigh, J. Mehrotra, M. A. Blum, J. Lange, A. Lapides, E. Garrett, P. Argani, and S. Sukumar
Quantitative Multiplex Methylation-Specific PCR Assay for the Detection of Promoter Hypermethylation in Multiple Genes in Breast Cancer
Cancer Res., July 1, 2004; 64(13): 4442 - 4452.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
C. A. Borgono, I. P. Michael, and E. P. Diamandis
Human Tissue Kallikreins: Physiologic Roles and Applications in Cancer
Mol. Cancer Res., May 1, 2004; 2(5): 257 - 280.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
H. G. Palmer, M. Sanchez-Carbayo, P. Ordonez-Moran, M. J. Larriba, C. Cordon-Cardo, and A. Munoz
Genetic Signatures of Differentiation Induced by 1{alpha},25-Dihydroxyvitamin D3 in Human Colon Cancer Cells
Cancer Res., November 15, 2003; 63(22): 7799 - 7806.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
G. M. Yousef, M.-E. Polymeris, L. Grass, A. Soosaipillai, P.-C. Chan, A. Scorilas, C. Borgono, N. Harbeck, B. Schmalfeldt, J. Dorn, et al.
Human Kallikrein 5: A Potential Novel Serum Biomarker for Breast and Ovarian Cancer
Cancer Res., July 15, 2003; 63(14): 3958 - 3965.
[Abstract] [Full Text] [PDF]


Home page
J. Histochem. Cytochem.Home page
C. D. Petraki, V. N. Karavana, L.-Y. Luo, and E. P. Diamandis
Human Kallikrein 10 Expression in Normal Tissues by Immunohistochemistry
J. Histochem. Cytochem., September 1, 2002; 50(9): 1247 - 1261.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.